TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04767256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and dexmedetomidine
Description: General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided lumbar erector spinae plane block
Description: The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar erector spinae plane block
Description: The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PCIA
Description: Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCIA
Description: Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
Study: NCT05078463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)
Description: 1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)
Description: 1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Finger Tip Unit (FTU) EMLA (15-minute application time)
Description: 1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)
Description: 0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Patch
Description: A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
Study: NCT05191823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
Description: 200 mg DHA+ 200 mg AA per day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg corn oil per day for 6 months
Study: NCT05903534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training
Description: Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Limb Strength Training Group
Description: Lower Limb Strength Training Group
Study: NCT06340958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLE-100
Description: 1 tablet of CLE-100 administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo administered once daily
Study: NCT05957627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saleem's protocol
Description: It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
Study: NCT05627037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant produced by additive manufacture
Description: In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant produced by additive manufacture
Description: In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
Study: NCT05136443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate 0.25% ophthalmic suspension
Description: tapering dose
Study: NCT05675956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group with 100% intensity setting on Apollo Neuro device
Description: The group will have the device set to 100% intensity at one of their two experimental visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator group with 10% intensity setting on the Apollo Neuro device
Description: The group will have the device set to 10% intensity at one of their two experimental visits.
Study: NCT06084117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNO
Description: Respiratory support with HFNO (as opposed to NIV, as per standard of care)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Respiratory support with Non-invasive ventilation, standard of care
Study: NCT03930680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: One dose of dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: One dose of dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: One dose of dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: One dose of dexrazoxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: One dose of dexrazoxane
Study: NCT05978830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound stimulation
Description: In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial ultrasound stimulation
Description: In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
Study: NCT05468944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal specimen extraction robotic surgery
Description: Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
Study: NCT05861050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT04847882

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
Study: NCT04899687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
Study: NCT05468944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal specimen extraction robotic surgery
Description: Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
Study: NCT05457933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
Study: NCT05199350

Intervention type: OTHER
Intervention: Device Name: ANSiscope
Description: Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
Study: NCT06530602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 D SPA (shoulder complex pain alignment) Moblization
Description: 3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Moblization (KaltenBorn)
Description: 3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
Study: NCT05861050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03973710

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei dietary supplement
Description: a commercial probiotic dietary supplement
Study: NCT04899687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
Study: NCT03973710

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: placebo with a similar appearance to probiotics supplement
Study: NCT05452473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDSS-assisted upper GI endoscopy
Description: Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
Study: NCT06545006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric contractions
Description: Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
Study: NCT06271213

Intervention type: OTHER
Intervention: observational only - no interventions as part of study
Description: Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.

Intervention type: OTHER
Intervention: observational only - no interventions as part of study
Description: Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.

Intervention type: OTHER
Intervention: observational only - no interventions as part of study
Description: Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.

Intervention type: OTHER
Intervention: observational only - no interventions as part of study
Description: Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.

Intervention type: OTHER
Intervention: observational only - no interventions as part of study
Description: Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
Study: NCT04443010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
Study: NCT05990569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Pudendal nerve block
Description: Ultrasound guided bilateral pudendal nerve block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Pudendal nerve block
Description: Ultrasound guided bilateral pudendal nerve block
Study: NCT05587309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Orally via tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI Control
Description: Orally via tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI Control
Description: Orally via tablet
Study: NCT06412926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 44-4400
Description: Film-coated tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 44-4400
Description: Film-coated tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 44-4400
Description: Film-coated tablet, oral use
Study: NCT04651244

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Gold standard for identifying inflammatory changes in patients with acute pyelonephritis

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound performed by a radiologist
Description: US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
Study: NCT06476925

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sonar guided stellate ganglion injection
Description: using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sonar guided stellate ganglion block
Description: using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
Study: NCT05989412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient health questionnaire-9 via the Your Research application
Description: Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient health questionnaire-9 via the Your Research application
Description: Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
Study: NCT05230680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHOP
Description: 1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total
Study: NCT05890521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell)
Description: Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person.